Context
The Union Government has banned 16 Fixed-Dose Combination (FDC) drugs, including certain antibiotic combinations and dermatological formulations, citing the absence of therapeutic justification, lack of supporting clinical evidence, potential safety risks, and the growing threat of antimicrobial resistance (AMR).
Fixed-Dose Combination (FDC) Drugs
A Fixed-Dose Combination (FDC) is a pharmaceutical formulation containing two or more active pharmaceutical ingredients (APIs) in fixed proportions within a single dosage form such as a tablet, capsule, syrup, or cream.
FDCs are widely prescribed for:
-
- Infectious diseases
- Pain and inflammation
- Skin disorders
- Diabetes
- Cardiovascular diseases
- Cough, cold, and fever
Rational and Irrational FDCs
Rational FDCs
A combination is considered rational when it:
- Has a well-defined therapeutic objective.
- Combines pharmacologically compatible drugs.
- Demonstrates superior efficacy, safety, or treatment adherence compared to individual medicines.
- Is supported by robust clinical evidence.
Irrational FDCs
A combination is considered irrational when it:
- Lacks scientific or therapeutic justification.
- Is not supported by adequate clinical evidence.
- Exposes patients to avoidable risks without improving clinical outcomes.
Regulatory Framework
- The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, is India’s apex drug regulatory authority.
- The Drugs and Cosmetics Act, 1940 regulates the approval, manufacture, and sale of medicines.
- Under the New Drugs and Clinical Trials Rules, 2019, FDCs are classified as new drugs and require prior approval from the CDSCO before marketing.
- Expert committees constituted by the Government periodically assess the safety and efficacy of marketed FDCs and recommend regulatory action where necessary.
- The Indian Council of Medical Research (ICMR) has consistently identified irrational FDCs as a significant contributor to antimicrobial resistance (AMR).
Reasons for the Ban
The prohibited formulations were found to:
- Lack adequate therapeutic justification.
- Result in unnecessary exposure to medicines without additional clinical benefit.
- Increase the risk of adverse drug reactions.
- Accelerate antimicrobial resistance.
- Increase treatment costs without improving patient outcomes.
Illustrative Examples
| Fixed-Dose Combination
|
Concern |
| Amoxicillin + Serratiopeptidase | No convincing clinical evidence demonstrates additional therapeutic benefit over amoxicillin alone. |
| Norfloxacin + Tinidazole | Treats infections that rarely occur together, resulting in unnecessary antimicrobial exposure. |
| Amoxicillin + Clavulanic Acid | Beneficial only where bacterial resistance is mediated by β-lactamase enzymes; indiscriminate use accelerates antimicrobial resistance. |
Public Health Concerns
- Antimicrobial Resistance (AMR)
Irrational antibiotic combinations:
- Increase unnecessary antibiotic consumption.
- Promote the emergence and spread of drug-resistant microorganisms.
- Reduce the clinical effectiveness of existing antibiotics.
- Limit future treatment options.
Irrational Dermatological Combinations
Several banned formulations combine aloe vera with ingredients such as Vitamin E, jojoba oil, olive oil, and tea tree oil.
Major concerns include:
- Lack of evidence demonstrating superior efficacy over individual ingredients.
- Irrational steroid-antifungal combinations may suppress local immunity, aggravate fungal infections, and delay appropriate treatment.
Risks Associated with Irrational FDCs
The use of irrational combinations may lead to:
- Adverse drug reactions and drug interactions.
- Allergic reactions due to unnecessary ingredients.
- Difficulty in optimising the dose of individual medicines.
- Masking of symptoms, delaying accurate diagnosis and appropriate treatment.
- Higher treatment costs without added therapeutic benefit.
Key Terms
- Fixed-Dose Combination (FDC): A medicine containing two or more active pharmaceutical ingredients in fixed proportions.
- Antimicrobial Resistance (AMR): The ability of microorganisms to survive medicines designed to eliminate them.
- Antimicrobial Stewardship: Coordinated interventions that promote appropriate antimicrobial use, improve treatment outcomes, and minimise the emergence of resistance.
- Rational Use of Medicines: Use of medicines appropriate to the patient’s clinical needs, in the correct dose and duration, at the lowest possible cost.
Way Forward
| Area
|
Measures |
| Regulatory Reforms | Strengthen scientific evaluation, periodic review of marketed FDCs, and post-marketing surveillance. |
| Clinical Practice | Promote evidence-based prescribing, adherence to standard treatment guidelines, and antimicrobial stewardship. |
| Research & Surveillance | Strengthen AMR surveillance and generate robust clinical evidence for FDCs. |
| Public Awareness | Encourage rational drug use, discourage self-medication, and improve awareness about banned formulations. |
Significance of the Ban
- Strengthens evidence-based pharmaceutical regulation.
- Promotes the rational use of medicines.
- Reduces unnecessary drug exposure and adverse effects.
- Supports national efforts to combat antimicrobial resistance.
- Encourages periodic scientific review of marketed medicines.
- Enhances patient safety and public health.
Conclusion
The ban on irrational Fixed-Dose Combination drugs marks a significant step towards evidence-based pharmaceutical regulation and rational prescribing. Eliminating scientifically unjustified drug combinations will improve patient safety, strengthen antimicrobial stewardship, and help preserve the long-term effectiveness of existing antimicrobials. Sustained regulatory vigilance, supported by scientific evidence and responsible prescribing practices, will be essential to ensure the safe and effective use of medicines in India.
